secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXICURE, INC. (XCUR)
CIK:        0001698530
Form:       8-K/A
Filed at:   2025-01-23T23:59:59+00:00
Accession:  0001698530-25-000006
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exicure acquires GPCR Therapeutics USA and signs license/collaboration agreement
--------------------------------------------------------------------------------

- Acquired all outstanding equity of GPCR Therapeutics USA from GPCR Therapeutics Inc.; deal closed concurrently with execution.
- Entered License and Collaboration Agreement to develop and commercialize GPCR's technologies and patents.
- Must make milestone payments tied to clinical trial, regulatory, and sales milestones; royalty of at least 10% of net sales.
- Corrected press release filed as an amendment to the January 22, 2025 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1698530/000169853025000006/0001698530-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1698530/000169853025000006/xcur-20250123.htm
  HTML page:      https://secwatch.observer/filing/0001698530-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer